Developer docs
API playgroundTry for free, no card

Search company profiles

ToolGen

Full company profile

uuid00088pn

Namestring
ToolGen
Legal namestring
주식회사 툴젠 (ToolGen Inc.)
Websiteurl
toolgen.com
Company typeenum
Public
Founded yearint
1999
Descriptiontext

ToolGen is a South Korea–headquartered, KOSDAQ-listed (ticker 199800) biotechnology company founded in 1999 by Dr. Jin-Soo Kim that develops and commercializes gene editing technology across three generations of platforms — ZFN (developed 2000), TALEN (developed 2011), and CRISPR-Cas9 (developed 2012). ToolGen is the world's first patent filer for CRISPR-Cas9 gene editing in eukaryotic cells and holds foundational patents in 9+ jurisdictions including the US, Europe, China, Japan, Korea, Australia, Singapore, India, and Hong Kong; its senior-party status in US PTAB interference proceedings with the Broad Institute was confirmed in 2022. The portfolio has expanded into CRISPR RNP delivery systems (US 12,612,632/633/634 and EP 3,346,003/EP 4,397,760), base and prime editor platforms, Sniper Cas9 (published in Nature Communications 2018), and C. jejuni Cas9 patents in the US and Australia.

The company operates four revenue streams across three business divisions: (1) Therapeutics — in vivo programs including GEB-200 (Lp(a) reduction cardiovascular therapy, partnered with GenEditBio via a November 2025 strategic cross-license), TGT-001 (Charcot-Marie-Tooth disease 1A), TG-LBP (hemophilia B), and an ex vivo next-generation CAR-T program; (2) Crops — gene-edited high-oleic acid soybeans (USDA non-GMO approved), browning-suppressed potatoes, herbicide-tolerant corn and soybeans, and specialty industrial/SAF feedstock crops developed through a KORIL-RDF-funded partnership with PlantArcBio; (3) Genome Editing Services — custom cell line production (knock-out, knock-in) and IVT RNA synthesis offered to research institutions and biotech firms at reported In/Del efficiencies of up to 60% (mixed pools) and 100% (single-cell clones); and (4) IP Licensing — royalty and upfront-bearing agreements with Monsanto/Bayer, Thermo Fisher Scientific, Life Technologies, KeyGene, Avinnogen, and others, with active litigation against Vertex Pharmaceuticals and the Broad Institute to monetize the foundational patent estate.

ToolGen's go-to-market is B2B licensing-led with channel partnerships and a small direct research services arm; distribution is direct and global, with offices in Seoul (headquarters, Magok BioInnovation Park) and an R&D center at the Osong Biohealth Complex in Cheongju. Management has publicly declared 2026 the 'Revenue Generation Phase,' backed by a ~700 billion KRW rights offering approved in May 2026 to fund litigation, R&D, and operational scaling, and supported by the appointment of US litigator Dave Boncheun Koo as Chief Legal Officer and the formation of a Science Advisory Board chaired scientifically by founder Dr. Jin-Soo Kim.

Short descriptiontext

ToolGen is a KOSDAQ-listed South Korean biotechnology company that holds foundational CRISPR-Cas9 gene editing patents for eukaryotic cells and operates across therapeutics (Lp(a), CMT, hemophilia, CAR-T), gene-edited crops, custom cell-line services, and a global IP licensing and litigation program.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
51–100
akta.pro rankint
HeadquartersSeoul, South Korea
HQ citystring
Seoul
HQ countrystring
South Korea
HQ regionstring
Asia
Markets served

Serves global market

Offices2 records

Each record includes

City, Country, Type, Description, Source

Keyword5 values
CRISPR gene editing, genome editing platform, biotech patent licensing, gene therapy development, crop biotechnology
Industry3 codes
PRIMARYHLAAACAD
Genome Editing Gene Therapies (CRISPR/TALEN/ZFN; in vivo/ex vivo)
Healthcare & Life Sciences/Biotechnology & Biologics/Gene Therapy (AAV/lentiviral/other vectors)
SECONDARYAFAGAIAG
Biotechnology & Gene-Edited Trait Development
Agriculture & Food Production/Crop Farming/Seed Production & Plant Breeding (Seed Multiplication, Hybrid Seed, Certified Seed)
SECONDARYHLAAACAN
Gene Therapy CMC/Process Development Platforms (capsid engineering, producer cell lines, plasmids, upstream/downstream)
Healthcare & Life Sciences/Biotechnology & Biologics/Gene Therapy (AAV/lentiviral/other vectors)
NAICS code2 codes
  • Research and Development in Biotechnology (except Nanobiotechnology)541714
  • Scientific Research and Development Services5417
SIC code2 codes
  • Patent Owners & Lessors6794
  • Services-Commercial Physical & Biological Research8731
Product category
Gene Editing Technology
Social media profiles2 records
GTM motion3 records

Each record includes

Type, Description, Source

Revenue model4 records
1Patent Licensing and Royalty Income
TypeLicensing Royalties
Description

ToolGen monetizes its foundational CRISPR-Cas9 patents through licensing agreements with global companies. Revenue comes from upfront payments, annual royalties, and milestone payments. The company has out-licensed to Monsanto (Bayer), Thermo Fisher Scientific, Life Technologies, and KeyGene. In 2026, management declared this the 'Revenue Generation Phase' targeting substantial recurring royalty income.

toolgen.com
2Co-development and Strategic Partnerships
TypeLicensing Royalties
Description

Joint development agreements with partners like GenEditBio for therapeutic programs (GEB-200) and PlantArcBio for agricultural applications. Revenue generated through shared development costs, milestone payments, and profit sharing from commercialization.

toolgen.com
3Genome Editing Services
TypeOne Time License
Description

Customized genome-edited cell line production and IVT RNA synthesis services offered to research institutions and biotech companies. Services include knock-out, knock-in cell lines with varying timelines and efficiency guarantees.

toolgen.com
4Seed Sales and Crop Development
TypeOne Time License
Description

Development and commercialization of gene-edited crops including soybeans, potatoes, corn, and specialty crops. Revenue from seed sales, trait licensing, and potentially vertical value chain integration in agricultural markets.

toolgen.com
Marketing channels4 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels4 records

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components5 values
Personnel, Technology or R&D, Operations, Marketing or Sales, Others
GTM typeB2B
B2B
Offering typeServices
Services
Core offering1 text field

ToolGen develops and commercializes CRISPR-Cas9 gene editing technology, holding foundational patents registered across 9+ key jurisdictions. The company operates three business divisions: an IP Business licensing CRISPR-Cas9 patents to global pharma, biotech, and seed companies; a Therapeutics division developing in vivo gene editing therapies (cardiovascular, rare disease) and ex vivo CAR-T cell therapies; and a Crop Science division producing gene-edited soybeans, potatoes, and specialty crops. ToolGen also offers custom genome-edited cell line production and IVT RNA synthesis services to research institutions and CROs.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 4 values shown
  • Patent registration in 9+ key jurisdictions validated by successful licensing to global companies
+3 more records
Product overview1 text field

ToolGen operates a platform-plus-services business model centered on its CRISPR-Cas9 foundational patent portfolio, which is registered in 10 key countries. The core technology platform powers three business divisions: Therapeutics (in vivo programs GEB-200, TGT-001, TG-LBP and ex vivo CAR-T), Crops (gene-edited soybean, potato, corn, and specialty oil crops), and Genome Editing Services (custom cell line production). The company also generates revenue through IP licensing to partners including Bayer and Thermo Fisher. The platform is differentiated by foundational patent priority confirmed by PTAB interference proceedings.

Product and service10 records
1CRISPR-Cas9 Platform
CategoryCore Technology Platform
Description

World-leading CRISPR-Cas9 gene editing technology platform with foundational patents in 10 countries including the US, Europe, China, Australia, and Japan, enabling precise modification of genetic information in eukaryotic cells.

2Genome Edited Cell Line Service
CategoryResearch Services
Description

Custom genome editing services for research institutions and biotech companies producing knock-out and knock-in cell lines using Cas9 protein (RNP) or mRNA transfection with highly specific sgRNA to minimize off-target effects.

3GEB-200
CategoryTherapeutic Pipeline
Description

In vivo genome editing therapy for atherosclerotic cardiovascular disease (ASCVD) targeting lipoprotein(a) [Lp(a)] reduction, developed through a strategic cross-license with GenEditBio using LNP delivery technology for a once-and-done treatment paradigm.

4TGT-001
CategoryTherapeutic Pipeline
Description

In vivo therapeutic program targeting Charcot-Marie-Tooth disease (CMT 1A), a hereditary peripheral neuropathy for which no approved cure currently exists.

5TG-LBP
CategoryTherapeutic Pipeline
Description

Liver-targeted in vivo genome editing program for hemophilia B that leverages CRISPR-Cas9 technology for a potential genomic cure.

6Next-generation CAR-T
CategoryEx Vivo Cell Therapy
Description

Ex vivo CAR-T cell therapy program using CRISPR-based cell engineering to enhance immune cell functionality for cancer treatment.

7High-oleic Acid Soybeans
CategoryCrop Pipeline
Description

Gene-edited soybean variety with enhanced oleic acid content providing improved oil stability and health benefits, with USDA Non-GMO approval enabling market access without GMO regulation.

8Browning-suppressed Potato
CategoryCrop Pipeline
Description

Gene-edited potato with suppressed browning trait providing improved fresh market appearance and reduced food waste, approved with GMO regulatory exemption from USDA.

9Herbicide Tolerant Crops (Corn/Soybean)
CategoryCrop Pipeline
Description

Gene-edited crops with herbicide tolerance traits for simplified weed management, part of a diversified crop portfolio targeting global industrial markets including potential SAF (sustainable aviation fuel) feedstock applications.

10CRISPR IP Licensing & Partnership Program
CategoryBusiness Service
Description

Licensing of CRISPR-Cas9 foundational patents to global pharmaceutical, biotechnology, and seed companies through strategic IP monetization including upfront payments, royalties, milestone payments, and patent enforcement.

Scale indicator4 records

Each record includes

Type, Value, Description, Source

Partnership9 partners
1Korean Gene Editing Industry Council
Strategic tierMinorTypeOthersAnnounced on2026-06-11
Description

ToolGen CEO serves as chairman of Gene Editing Bioindustry Development Council, an industry association of 30+ companies including ToolGen, Greenjin, Nullabio, Davigene, Lasemia, Ratbio, Mujinmedi, Bio니아, Biod, and others. Council advocates for favorable regulation of gene-edited organisms in Korea.

toolgen.com
Strategic tierCoreTypeOthersAnnounced on2026-03-25
Description

Formed Science Advisory Board (SAB) with top researchers: Dr. Jin-Soo Kim (KAIST, founder), Prof. Kim Hyung-bum (Yonsei University College of Medicine), and Prof. Lim Yong-pyo (Konkuk University, former Golden Seed Project vegetable seed business unit director). SAB to advise on technology strategy and commercialization.

Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2025-11-20
Description

Strategic cross-license agreement combining ToolGen's CRISPR-Cas9 platform with GenEditBio's LNP delivery technology for in-vivo genome editing therapeutics. Jointly developing GEB-200 for cardiovascular disease (Lp(a) reduction). Successfully completed NHP proof-of-concept study. Both parties will share development costs and commercialization revenues.

Strategic tierMinorTypeOEM/ Whitelabel/ Licensing PartnerAnnounced on2025-11-06
Description

Technology licensing agreement for CRISPR-Cas9 gene editor to Seoul National University spinout for disease-resistant poultry breeding and production of therapeutic proteins in eggs using avian germline editing. ToolGen receives upfront payment and royalties on sales.

Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2024-12-04
Description

Strategic collaboration to develop gene-edited herbicide-tolerant soybeans using CRISPR-Cas9 and PlantArcBio's DIPPER platform. Two-year project funded with US$2.16 million by KORIL-RDF (Korea-Israel Industrial R&D Foundation). Targets $10 billion global soybean seed market with non-GMO weed management solution.

6Monsanto (Now Bayer)
Strategic tierCoreTypeOEM/ Whitelabel/ Licensing PartnerAnnounced on2017-01-01
Description

License-out of CRISPR gene editing technology for agricultural applications. Major enterprise customer validating ToolGen's foundational patents in agricultural biotechnology.

toolgen.com
Strategic tierCoreTypeOEM/ Whitelabel/ Licensing PartnerAnnounced on2014-11-01
Description

License-out of CRISPR gene editing technology for research tools and life science reagent manufacturing. Validates ToolGen's foundational patent portfolio globally.

Strategic tierMinorTypeOEM/ Whitelabel/ Licensing PartnerAnnounced on2013-07-01
Description

License-out of CRISPR gene editing technology for agricultural crop research and development in Netherlands. Strategic partnership for European agricultural market access.

9Life Technologies (Now Thermo Fisher)
Strategic tierCoreTypeOEM/ Whitelabel/ Licensing PartnerAnnounced on2013-01-01
Description

Early license-out of CRISPR gene editing technology for life science research applications in the United States. One of the first major validation of ToolGen's patent portfolio.

toolgen.com
Recent move8 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight6 records

Each record includes

Type, Description

Peers10 records
TypeDirect peer
Description

Clinical-stage CRISPR-Cas9 and Cas12a gene editing company developing in vivo and ex vivo therapeutics. Direct competitor to ToolGen in CRISPR therapeutics, with overlapping foundational IP positions and target indications including sickle cell disease.

TypeDirect peer
Description

Clinical-stage cardiovascular gene editing company (now Eli Lilly following $1B upfront acquisition in 2025) developing in vivo base editing therapies for atherosclerotic cardiovascular disease. Direct program-level peer to ToolGen's GEB-200 Lp(a) reduction program and validates the cardiovascular gene editing TAM ToolGen targets.

TypeDirect peer
Description

Clinical-stage gene editing company that co-invented TALEN technology. Direct peer to ToolGen's second-generation TALEN heritage and an active competitor in ex vivo CAR-T and gene therapy programs using engineered nucleases.

TypeDirect peer
Description

Clinical-stage in vivo CRISPR-Cas9 gene editing company developing NTLA-2001 (transthyretin amyloidosis) and other systemic editing programs. Direct competitor to ToolGen's GEB-200 (Lp(a) reduction) and other liver-targeted in vivo programs using LNP delivery.

TypeDirect peer
Description

Clinical-stage allogeneic CAR-T cell therapy company using CRISPR-Cas9 chRDNA platform. Direct peer to ToolGen's ex vivo CAR-T program and a comparable CRISPR platform-plus-pipeline biotech with similar headcount and stage profile.

TypeDirect peer
Description

Clinical-stage base editing company founded by David Liu, developing precision gene editing medicines. Direct technology competitor to ToolGen's disclosed base editor and prime editor platform extensions, with comparable platform-plus-pipeline structure.

TypeDirect peer
Description

Clinical-stage CRISPR-Cas9 gene editing company co-developing Casgevy (exa-cel) with Vertex. Direct competitor to ToolGen in CRISPR-based therapeutics and the most relevant benchmark for ToolGen's foundational patent licensing value, particularly given Vertex's role as a counterparty to both companies.

TypeDirect peer
Description

Clinical-stage gene editing and gene therapy company originally pioneering Zinc Finger Nuclease (ZFN) technology. Direct peer to ToolGen's first-generation ZFN heritage and the original ZFN platform from which ToolGen's lineage evolved before TALEN and CRISPR.

TypeEmerging player
Description

Agricultural biotechnology company using CRISPR-Cas9 and base editing to develop gene-edited crops, including seedless blackberries and pitless cherries. Direct peer to ToolGen's crop pipeline (herbicide-tolerant soybeans, browning-suppressed potatoes) with comparable non-GMO regulatory positioning in the US.

TypeEmerging player
Description

Agricultural biotechnology company using proprietary genomics and gene editing (including CRISPR-based approaches) to develop improved soybean and other crop varieties. Comparable peer to ToolGen's high-oleic-acid soybean and broader crop science business unit targeting the same seed company customer base.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat4 records

Each record includes

Type, Details

Key risks7 records

Each record includes

Headline, Details, Source

Key highlights7 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers5 records

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment4 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile4 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature5 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles7 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds2 records

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors2 records

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

ToolGen

Gene Editing Technologytoolgen.com

ToolGen is a KOSDAQ-listed South Korean biotechnology company that holds foundational CRISPR-Cas9 gene editing patents for eukaryotic cells and operates across therapeutics (Lp(a), CMT, hemophilia, CAR-T), gene-edited crops, custom cell-line services, and a global IP licensing and litigation program.

What ToolGen does

ToolGen is a South Korea–headquartered, KOSDAQ-listed (ticker 199800) biotechnology company founded in 1999 by Dr. Jin-Soo Kim that develops and commercializes gene editing technology across three generations of platforms — ZFN (developed 2000), TALEN (developed 2011), and CRISPR-Cas9 (developed 2012). ToolGen is the world's first patent filer for CRISPR-Cas9 gene editing in eukaryotic cells and holds foundational patents in 9+ jurisdictions including the US, Europe, China, Japan, Korea, Australia, Singapore, India, and Hong Kong; its senior-party status in US PTAB interference proceedings with the Broad Institute was confirmed in 2022. The portfolio has expanded into CRISPR RNP delivery systems (US 12,612,632/633/634 and EP 3,346,003/EP 4,397,760), base and prime editor platforms, Sniper Cas9 (published in Nature Communications 2018), and C. jejuni Cas9 patents in the US and Australia.

The company operates four revenue streams across three business divisions: (1) Therapeutics — in vivo programs including GEB-200 (Lp(a) reduction cardiovascular therapy, partnered with GenEditBio via a November 2025 strategic cross-license), TGT-001 (Charcot-Marie-Tooth disease 1A), TG-LBP (hemophilia B), and an ex vivo next-generation CAR-T program; (2) Crops — gene-edited high-oleic acid soybeans (USDA non-GMO approved), browning-suppressed potatoes, herbicide-tolerant corn and soybeans, and specialty industrial/SAF feedstock crops developed through a KORIL-RDF-funded partnership with PlantArcBio; (3) Genome Editing Services — custom cell line production (knock-out, knock-in) and IVT RNA synthesis offered to research institutions and biotech firms at reported In/Del efficiencies of up to 60% (mixed pools) and 100% (single-cell clones); and (4) IP Licensing — royalty and upfront-bearing agreements with Monsanto/Bayer, Thermo Fisher Scientific, Life Technologies, KeyGene, Avinnogen, and others, with active litigation against Vertex Pharmaceuticals and the Broad Institute to monetize the foundational patent estate.

ToolGen's go-to-market is B2B licensing-led with channel partnerships and a small direct research services arm; distribution is direct and global, with offices in Seoul (headquarters, Magok BioInnovation Park) and an R&D center at the Osong Biohealth Complex in Cheongju. Management has publicly declared 2026 the 'Revenue Generation Phase,' backed by a ~700 billion KRW rights offering approved in May 2026 to fund litigation, R&D, and operational scaling, and supported by the appointment of US litigator Dave Boncheun Koo as Chief Legal Officer and the formation of a Science Advisory Board chaired scientifically by founder Dr. Jin-Soo Kim.

ToolGen firmographics

Firmographics
Name
ToolGen
Legal name
주식회사 툴젠 (ToolGen Inc.)
Website
https://toolgen.com
Company type
Public
Founded year
1999
Operating status
Operating
Headcount range
51–100 employees
Short description
ToolGen is a KOSDAQ-listed South Korean biotechnology company that holds foundational CRISPR-Cas9 gene editing patents for eukaryotic cells and operates across therapeutics (Lp(a), CMT, hemophilia, CAR-T), gene-edited crops, custom cell-line services, and a global IP licensing and litigation program.
Ownership category
akta.pro rank

ToolGen industry classification

Industry
Product category
Gene Editing Technology
NAICS
Research and Development in Biotechnology (except Nanobiotechnology) (541714), Scientific Research and Development Services (5417)
SIC
Patent Owners & Lessors (6794), Services-Commercial Physical & Biological Research (8731)
akta.pro industry
PRIMARYHLAAACAD
Genome Editing Gene Therapies (CRISPR/TALEN/ZFN; in vivo/ex vivo)
Healthcare & Life Sciences/Biotechnology & Biologics/Gene Therapy (AAV/lentiviral/other vectors)
SECONDARYAFAGAIAG
Biotechnology & Gene-Edited Trait Development
Agriculture & Food Production/Crop Farming/Seed Production & Plant Breeding (Seed Multiplication, Hybrid Seed, Certified Seed)
SECONDARYHLAAACAN
Gene Therapy CMC/Process Development Platforms (capsid engineering, producer cell lines, plasmids, upstream/downstream)
Healthcare & Life Sciences/Biotechnology & Biologics/Gene Therapy (AAV/lentiviral/other vectors)

Keywords

  • CRISPR gene editing
  • Genome editing platform
  • Biotech patent licensing
  • Gene therapy development
  • Crop biotechnology

Where ToolGen is headquartered

Location

Headquarters

HQ city
Seoul
HQ country
South Korea
HQ region
Asia

Offices2 records

Markets served

ToolGen business model

Business model
GTM type
B2B
Offering type
Services
Cost components
Personnel, Technology or R&D, Operations, Marketing or Sales, Others

Revenue model

  1. Patent Licensing and Royalty Income: ToolGen monetizes its foundational CRISPR-Cas9 patents through licensing agreements with global companies. Revenue comes from upfront payments, annual royalties, and milestone payments. The company has out-licensed to Monsanto (Bayer), Thermo Fisher Scientific, Life Technologies, and KeyGene. In 2026, management declared this the 'Revenue Generation Phase' targeting substantial recurring royalty income.
  2. Co-development and Strategic Partnerships: Joint development agreements with partners like GenEditBio for therapeutic programs (GEB-200) and PlantArcBio for agricultural applications. Revenue generated through shared development costs, milestone payments, and profit sharing from commercialization.
  3. Genome Editing Services: Customized genome-edited cell line production and IVT RNA synthesis services offered to research institutions and biotech companies. Services include knock-out, knock-in cell lines with varying timelines and efficiency guarantees.
  4. Seed Sales and Crop Development: Development and commercialization of gene-edited crops including soybeans, potatoes, corn, and specialty crops. Revenue from seed sales, trait licensing, and potentially vertical value chain integration in agricultural markets.

Go-to-market motion3 records

Distribution channels4 records

Marketing channels4 records

ToolGen product offering

Product offering

Core offering

ToolGen develops and commercializes CRISPR-Cas9 gene editing technology, holding foundational patents registered across 9+ key jurisdictions. The company operates three business divisions: an IP Business licensing CRISPR-Cas9 patents to global pharma, biotech, and seed companies; a Therapeutics division developing in vivo gene editing therapies (cardiovascular, rare disease) and ex vivo CAR-T cell therapies; and a Crop Science division producing gene-edited soybeans, potatoes, and specialty crops. ToolGen also offers custom genome-edited cell line production and IVT RNA synthesis services to research institutions and CROs.

Product overview

ToolGen operates a platform-plus-services business model centered on its CRISPR-Cas9 foundational patent portfolio, which is registered in 10 key countries. The core technology platform powers three business divisions: Therapeutics (in vivo programs GEB-200, TGT-001, TG-LBP and ex vivo CAR-T), Crops (gene-edited soybean, potato, corn, and specialty oil crops), and Genome Editing Services (custom cell line production). The company also generates revenue through IP licensing to partners including Bayer and Thermo Fisher. The platform is differentiated by foundational patent priority confirmed by PTAB interference proceedings.

Differentiator

Problem solved

Functional benefit

Products and services

  • CRISPR-Cas9 Platform World-leading CRISPR-Cas9 gene editing technology platform with foundational patents in 10 countries including the US, Europe, China, Australia, and Japan, enabling precise modification of genetic information in eukaryotic cells.
  • Genome Edited Cell Line Service Custom genome editing services for research institutions and biotech companies producing knock-out and knock-in cell lines using Cas9 protein (RNP) or mRNA transfection with highly specific sgRNA to minimize off-target effects.
  • GEB-200 In vivo genome editing therapy for atherosclerotic cardiovascular disease (ASCVD) targeting lipoprotein(a) [Lp(a)] reduction, developed through a strategic cross-license with GenEditBio using LNP delivery technology for a once-and-done treatment paradigm.
  • TGT-001 In vivo therapeutic program targeting Charcot-Marie-Tooth disease (CMT 1A), a hereditary peripheral neuropathy for which no approved cure currently exists.
  • TG-LBP Liver-targeted in vivo genome editing program for hemophilia B that leverages CRISPR-Cas9 technology for a potential genomic cure.
  • Next-generation CAR-T Ex vivo CAR-T cell therapy program using CRISPR-based cell engineering to enhance immune cell functionality for cancer treatment.
  • High-oleic Acid Soybeans Gene-edited soybean variety with enhanced oleic acid content providing improved oil stability and health benefits, with USDA Non-GMO approval enabling market access without GMO regulation.
  • Browning-suppressed Potato Gene-edited potato with suppressed browning trait providing improved fresh market appearance and reduced food waste, approved with GMO regulatory exemption from USDA.
  • Herbicide Tolerant Crops (Corn/Soybean) Gene-edited crops with herbicide tolerance traits for simplified weed management, part of a diversified crop portfolio targeting global industrial markets including potential SAF (sustainable aviation fuel) feedstock applications.
  • CRISPR IP Licensing & Partnership Program Licensing of CRISPR-Cas9 foundational patents to global pharmaceutical, biotechnology, and seed companies through strategic IP monetization including upfront payments, royalties, milestone payments, and patent enforcement.

Quantifiable outcome

  • Patent registration in 9+ key jurisdictions validated by successful licensing to global companies
  • +3 more outcomes

Companies that use ToolGen

Customer profile

Named customers5 records

Segments4 records

Ideal customer profiles4 records

ToolGen technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature5 records

ToolGen partnerships and signals

Strategic signal

Partnerships

Nine partnerships are on record, tiered minor and core.

  • Korean Gene Editing Industry CouncilminorOthers · 11 June 2026ToolGen CEO serves as chairman of Gene Editing Bioindustry Development Council, an industry association of 30+ companies including ToolGen, Greenjin, Nullabio, Davigene, Lasemia, Ratbio, Mujinmedi, Bio니아, Biod, and others. Council advocates for favorable regulation of gene-edited organisms in Korea.
  • Science Advisory Board MemberscoreOthers · 25 March 2026Formed Science Advisory Board (SAB) with top researchers: Dr. Jin-Soo Kim (KAIST, founder), Prof. Kim Hyung-bum (Yonsei University College of Medicine), and Prof. Lim Yong-pyo (Konkuk University, former Golden Seed Project vegetable seed business unit director). SAB to advise on technology strategy and commercialization.
  • GenEditBiocoreStrategic or Co-development Partner · 20 November 2025Strategic cross-license agreement combining ToolGen's CRISPR-Cas9 platform with GenEditBio's LNP delivery technology for in-vivo genome editing therapeutics. Jointly developing GEB-200 for cardiovascular disease (Lp(a) reduction). Successfully completed NHP proof-of-concept study. Both parties will share development costs and commercialization revenues.
  • AvinnogenminorOEM/ Whitelabel/ Licensing Partner · 6 November 2025Technology licensing agreement for CRISPR-Cas9 gene editor to Seoul National University spinout for disease-resistant poultry breeding and production of therapeutic proteins in eggs using avian germline editing. ToolGen receives upfront payment and royalties on sales.
  • PlantArcBiocoreStrategic or Co-development Partner · 4 December 2024Strategic collaboration to develop gene-edited herbicide-tolerant soybeans using CRISPR-Cas9 and PlantArcBio's DIPPER platform. Two-year project funded with US$2.16 million by KORIL-RDF (Korea-Israel Industrial R&D Foundation). Targets $10 billion global soybean seed market with non-GMO weed management solution.
  • Monsanto (Now Bayer)coreOEM/ Whitelabel/ Licensing Partner · 1 January 2017License-out of CRISPR gene editing technology for agricultural applications. Major enterprise customer validating ToolGen's foundational patents in agricultural biotechnology.
  • Thermo Fisher ScientificcoreOEM/ Whitelabel/ Licensing Partner · 1 November 2014License-out of CRISPR gene editing technology for research tools and life science reagent manufacturing. Validates ToolGen's foundational patent portfolio globally.
  • KeyGeneminorOEM/ Whitelabel/ Licensing Partner · 1 July 2013License-out of CRISPR gene editing technology for agricultural crop research and development in Netherlands. Strategic partnership for European agricultural market access.
  • Life Technologies (Now Thermo Fisher)coreOEM/ Whitelabel/ Licensing Partner · 1 January 2013Early license-out of CRISPR gene editing technology for life science research applications in the United States. One of the first major validation of ToolGen's patent portfolio.

Scale indicators4 records

Recent moves8 records

Expansion highlights6 records

ToolGen competitors and assessment

Company assessment

Direct peers

  • Editas Medicine: Clinical-stage CRISPR-Cas9 and Cas12a gene editing company developing in vivo and ex vivo therapeutics. Direct competitor to ToolGen in CRISPR therapeutics, with overlapping foundational IP positions and target indications including sickle cell disease.
  • Verve Therapeutics: Clinical-stage cardiovascular gene editing company (now Eli Lilly following $1B upfront acquisition in 2025) developing in vivo base editing therapies for atherosclerotic cardiovascular disease. Direct program-level peer to ToolGen's GEB-200 Lp(a) reduction program and validates the cardiovascular gene editing TAM ToolGen targets.
  • Cellectis: Clinical-stage gene editing company that co-invented TALEN technology. Direct peer to ToolGen's second-generation TALEN heritage and an active competitor in ex vivo CAR-T and gene therapy programs using engineered nucleases.
  • Intellia Therapeutics: Clinical-stage in vivo CRISPR-Cas9 gene editing company developing NTLA-2001 (transthyretin amyloidosis) and other systemic editing programs. Direct competitor to ToolGen's GEB-200 (Lp(a) reduction) and other liver-targeted in vivo programs using LNP delivery.
  • Caribou Biosciences: Clinical-stage allogeneic CAR-T cell therapy company using CRISPR-Cas9 chRDNA platform. Direct peer to ToolGen's ex vivo CAR-T program and a comparable CRISPR platform-plus-pipeline biotech with similar headcount and stage profile.
  • Beam Therapeutics: Clinical-stage base editing company founded by David Liu, developing precision gene editing medicines. Direct technology competitor to ToolGen's disclosed base editor and prime editor platform extensions, with comparable platform-plus-pipeline structure.
  • CRISPR Therapeutics: Clinical-stage CRISPR-Cas9 gene editing company co-developing Casgevy (exa-cel) with Vertex. Direct competitor to ToolGen in CRISPR-based therapeutics and the most relevant benchmark for ToolGen's foundational patent licensing value, particularly given Vertex's role as a counterparty to both companies.
  • Sangamo Therapeutics: Clinical-stage gene editing and gene therapy company originally pioneering Zinc Finger Nuclease (ZFN) technology. Direct peer to ToolGen's first-generation ZFN heritage and the original ZFN platform from which ToolGen's lineage evolved before TALEN and CRISPR.

Emerging players

  • Pairwise: Agricultural biotechnology company using CRISPR-Cas9 and base editing to develop gene-edited crops, including seedless blackberries and pitless cherries. Direct peer to ToolGen's crop pipeline (herbicide-tolerant soybeans, browning-suppressed potatoes) with comparable non-GMO regulatory positioning in the US.
  • Benson Hill: Agricultural biotechnology company using proprietary genomics and gene editing (including CRISPR-based approaches) to develop improved soybean and other crop varieties. Comparable peer to ToolGen's high-oleic-acid soybean and broader crop science business unit targeting the same seed company customer base.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat4 records

Key risks7 records

Key highlights7 records

Customer concentration

ToolGen social profiles

Digital presence

ToolGen financial estimates

Financial estimate

Revenue estimate

Valuation estimate

ToolGen leadership team

Management profile

Number of profiles

Profiles7 records

ToolGen funding detail

Funding detail

Funding overview

Funding rounds2 records

Investors2 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

ToolGen M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about ToolGen

What does ToolGen do?

ToolGen develops and commercializes CRISPR-Cas9 gene editing technology, holding foundational patents registered across 9+ key jurisdictions. The company operates three business divisions: an IP Business licensing CRISPR-Cas9 patents to global pharma, biotech, and seed companies; a Therapeutics division developing in vivo gene editing therapies (cardiovascular, rare disease) and ex vivo CAR-T cell therapies; and a Crop Science division producing gene-edited soybeans, potatoes, and specialty crops. ToolGen also offers custom genome-edited cell line production and IVT RNA synthesis services to research institutions and CROs.

Is ToolGen a public or private company?

ToolGen is a public company. It is classified as public and is currently operating.

When was ToolGen founded?

ToolGen was founded in 1999. It employs 51 to 100 people.

Where is ToolGen based?

ToolGen is headquartered in Seoul, South Korea, in the Asia region.

How does ToolGen make money?

Four revenue lines are on record. Patent Licensing and Royalty Income is the primary driver. The others are co-development and Strategic Partnerships, genome Editing Services and seed Sales and Crop Development.

Who are ToolGen's main competitors?

Direct peers on record are Editas Medicine, Verve Therapeutics, Cellectis, Intellia Therapeutics, Caribou Biosciences, Beam Therapeutics, CRISPR Therapeutics and Sangamo Therapeutics. Emerging players are Pairwise and Benson Hill.

Does ToolGen have an API?

No public API is recorded for ToolGen.

What industry is ToolGen in?

ToolGen's product category is Gene Editing Technology. Its primary akta.pro industry code is HLAAACAD, Genome Editing Gene Therapies (CRISPR/TALEN/ZFN; in vivo/ex vivo), with a secondary code of AFAGAIAG, Biotechnology & Gene-Edited Trait Development. Its NAICS code is 541714 and its SIC code is 6794.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
AInvestToolGen's Capital Raise Reveals the Math Behind Its Patent WarToolGen sought KRW 70 billion via a rights offering to fund CRISPR patent lawsuits against Vertex, but the stock fell 63% to KRW 32,500, creating a threefold gap. The company needs KRW 20 billion annually for litigation, and its revenue has declined from KRW 93.8 billion in 2023 to KRW 61.8 billion in 2025.PR.comDNA Harvest Partners and ToolGen Announce Strategic Partnership to Accelerate AI-Guided Predictive Breeding for Gene-Edited CropsDNA Harvest Partners and ToolGen announced a strategic partnership to accelerate AI-guided predictive breeding for gene-edited rapeseed. DNAHP will deploy its SmartCross platform and GEO framework to optimize genetic backgrounds, aiming to reduce development timelines and costs. The collaboration targets improving trait penetrance and field success for ToolGen's crop program.PR Newswire APACToolGen Opens Advanced Field Testing Facility in Osong, Completing 'Bench-to-Field' Commercialization Platform for Global SAF and Industrial Crop MarketsToolGen inaugurated a genome-edited crop field testing facility in Osong, South Korea, to accelerate commercialization. The facility will evaluate drought and herbicide tolerance and enhanced oil content in industrial oilseed crops for sustainable aviation fuel feedstocks. ToolGen is building an integrated vertical value chain targeting Australia, Southeast Asia, and Europe.AsiaeFDA Eases Uncertainty in Gene Therapy Regulations... Green Light for Korean Companies Like Toolgen to Enter Global MarketsThe FDA's Center for Biologics Evaluation and Research (CBER) released draft safety guidelines for customized gene therapies targeting ultra-rare diseases, establishing standardized evaluation criteria for off-target events in gene editing using next-generation sequencing technology. The guidelines clarify non-clinical research data requirements for IND and BLA submissions, reducing regulatory uncertainty that has complicated clinical trial design for new drug developers. Korean gene-editing companies including Toolgen, Jincore, Gplus Life Sciences, and Etgen can now collect data meeting global standards, enabling them to accelerate U.S. market entry and strengthen their negotiating position for technology exports.PR NewswireToolGen betreedt 'oogstfase' voor wereldwijde IP-monetisatie en benoemt proces- en onderhandelingsexpert Dave Koo tot CLOToolGen, a biotech company specializing in gene editing, announced the appointment of Dave Koo as its new Chief Legal Officer to lead worldwide patent enforcement and licensing efforts. The company aims to convert its extensive patent portfolio into consistent revenue streams through legal actions and negotiations, with ongoing patent procedures in the US, UK, and Netherlands.PR NewswireToolGen Enters 'Harvest Season' for Global IP Monetization; Appoints Litigation & Negotiation Expert Dave Koo as CLOToolGen appointed Dave Boncheun Koo as Chief Legal Officer to lead its global patent litigation and licensing efforts. The company aims to monetize its expanded CRISPR patent portfolio through legal actions and negotiations, focusing on major jurisdictions like the U.S., UK, and the Netherlands.PR NewswireToolGen Enters 'Harvest Season' for Global IP Monetization; Appoints Litigation & Negotiation Expert Dave Koo as CLOToolGen, a South Korean gene-editing technology company, has appointed Dave Boncheun Koo, a U.S. attorney and expert in international litigation and negotiation, as Chief Legal Officer to lead global patent monetization efforts. The company has been strengthening its CRISPR RNP patent portfolio and secured a PTAB ruling to resume U.S. Interference proceedings, positioning it to aggressively pursue patent infringement actions filed against Vertex in the UK, Netherlands, and U.S. courts in 2025. ToolGen's management has formally declared this its "Revenue Generation Phase," aiming to convert its foundational gene-editing patents into substantial and recurring royalty income from global companies.MorningstarToolGen Enters 'Harvest Season' for Global IP Monetization; Appoints Litigation & Negotiation Expert Dave Koo as CLOToolGen, a Korean gene-editing technology company, has appointed Dave Boncheun Koo, a U.S. attorney with over 25 years of international litigation experience, as Chief Legal Officer and Executive Vice President to lead global patent monetization efforts. The company is pursuing patent infringement actions against Vertex in the UK, Netherlands, and U.S., and is resuming U.S. Interference proceedings to defend its CRISPR technology patents. ToolGen has positioned this as entering a "Revenue Generation Phase" following the strengthening of its patent portfolio through 2025.EipBeyond CRISPR‑Cas9: The Emerging Platform Era of Gene EditingGene editing technology has evolved from CRISPR-Cas9 to next-generation base and prime editing tools, with Vertex Pharmaceuticals' Casgevy becoming the first approved CRISPR therapy for sickle cell disease and beta-thalassemia, gaining regulatory approvals in the UK, US, and EU between November 2023 and February 2024. The foundational CRISPR patents remain contested among CVC Group, ToolGen, Broad Institute/Harvard/MIT, and Sigma-Aldrich, while the field is now shifting toward scalable disease-agnostic platforms that could address both rare and common diseases, though current treatments face cost barriers exemplified by Casgevy's $2.2 million per-patient price tag. David Liu's lab published research on PERT technology in late 2025 as a single-agent approach to address nonsense mutations, and foundational Cas9 patents are expected to expire by mid-2030s, potentially reshaping the intellectual property landscape.PR NewswireToolGen and GenEditBio Enter Strategic Cross-License Agreement to Accelerate Development of Innovative Genome-Editing TherapeuticsToolGen Inc., a Korean genome editing company listed on KOSDAQ, and GenEditBio Limited, a Hong Kong-headquartered clinical-stage biotechnology company, have entered into a strategic cross-license agreement combining ToolGen's CRISPR-Cas9 genome editing platform with GenEditBio's lipid nanoparticle (LNP) delivery technology for developing in vivo genome-editing therapeutics. The two companies announced they recently completed a successful proof-of-concept study in non-human primates for their lead program GEB-200, an investigational therapy targeting lipoprotein(a) to treat atherosclerotic cardiovascular disease, representing a key milestone toward IND submission. The companies plan to accelerate the regulatory path for GEB-200 and jointly explore global licensing opportunities under the agreement.